16 completed, 5 terminated, 1 unknown. 15 Phase 2, 4 Phase 3, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 9, Terminated 5, Unknown 1 |
| Phase 3 | 4 | Completed 4 |
| Phase 4 | 2 | Completed 2 |
| Phase 1 | 1 | Terminated 1 |
Follow microplasmin: new trials by email Literature Review of microplasmin trials Research Report on microplasmin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection - Diabetic Retinopathy, Posterior Vitreous Detachment | Phase 2 | Terminated | ThromboGenics | 48 | 2015-12-01 | 2020-12-16 |
| Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion Ocriplasmin 0.125 mg in a 0.1 mL volume - Vitreomacular Traction, Vitreomacular Adhesion | Phase 4 | Completed | Alcon Research | 62 | 2015-05-26 | 2018-08-21 |
| Assessment of Patients Treated With JETREA® for Vitreomacular Traction Ocriplasmin - Vitreomacular Traction, Vitreomacular Adhesion | Phase 4 | Completed | Alcon Research | 628 | 2014-04-01 | 2016-10-12 |
| A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion Ocriplasmin, Sham injection - Symptomatic Vitreomacular Adhesion | Phase 3 | Completed | Alcon Research | 251 | 2013-07-01 | 2015-11-30 |
| Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole Ocriplasmin, Sham injection - Vitreomacular Adhesion Including Macular Hole | Phase 3 | Completed | ThromboGenics | 220 | 2011-10-01 | 2016-03-14 |
| Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies ocriplasmin, placebo - Symptomatic Vitreomacular Adhesion | Completed | ThromboGenics | 24 | 2011-05-01 | 2017-01-13 | |
| Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema Microplasmin - Uveitis | Phase 1 / Phase 2 | Terminated | National Institutes of Health Clinical Center (CC) | 2 | 2011-01-01 | 2018-07-31 |
| The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV) ocriplasmin - Vitrectomy | Phase 2 | Completed | ThromboGenics | 38 | 2010-07-01 | 2014-12-17 |
| Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy Ocriplasmin, Placebo - Vitrectomy | Phase 2 | Completed | ThromboGenics | 24 | 2010-02-01 | 2014-12-17 |
| Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion Ocriplasmin, Sham injection - Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion | Phase 2 | Completed | ThromboGenics | 100 | 2010-01-01 | 2014-12-17 |
| Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion Microplasmin - Focal Vitreomacular Adhesion | Phase 2 | Completed | ThromboGenics | 17 | 2010-01-01 | 2014-04-07 |
| Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration Microplasmin, Placebo control - Macular Degeneration | Phase 2 | Unknown | University of California, Los Angeles | 30 | 2009-10-01 | 2011-09-27 |
| Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial. Ocriplasmin 125µg, Placebo - Vitreomacular Adhesion | Phase 3 | Completed | ThromboGenics | 326 | 2008-12-01 | 2014-12-17 |
| Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial. 125 µg Ocriplasmin, Placebo - Vitreomacular Adhesion | Phase 3 | Completed | ThromboGenics | 326 | 2008-12-01 | 2014-12-17 |
| Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT microplasmin - Deep Vein Thrombosis | Phase 2 | Terminated | ThromboGenics | 6 | 2007-03-01 | 2014-04-07 |
| A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt) ocriplasmin, Sham Comparator - Vitreomacular Traction | Phase 2 | Completed | ThromboGenics | 60 | 2007-02-01 | 2014-12-17 |
| A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME) ocriplasmin, Sham injection - Diabetic Macular Edema | Phase 2 | Completed | ThromboGenics | 51 | 2006-12-01 | 2014-12-17 |
| A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III) Ocriplasmin 25µg, Ocriplasmin 75µg, Ocriplasmin 125µg - Vitrectomy | Phase 2 | Completed | ThromboGenics | 125 | 2006-12-01 | 2014-12-17 |
| Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion Microplasmin - Stroke | Phase 2 | Terminated | ThromboGenics | 2 | 2006-12-01 | 2014-04-07 |
| Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke Microplasmin - Stroke, Acute | Phase 2 | Completed | ThromboGenics | 40 | 2005-10-01 | 2014-11-07 |
Showing 20 of 22. Sign in to see all of them.
Diabetic Retinopathy (2) · Macular Degeneration (2) · Retinal Perforations (2) · Stroke (2) · Arterial Occlusive Diseases (1) · Disease Progression (1) · Eye Diseases (1) · Ischemic Stroke (1) · Macular Edema (1) · Scotoma (1) · Thromboembolism (1) · Uveitis (1) · Venous Thrombosis (1) · Vitreous Detachment (1)
ThromboGenics (17) · Alcon Research (3) · National Institutes of Health Clinical Center (CC) (1) · University of California, Los Angeles (1)
Belgium (10) · United States (10) · Germany (7) · United Kingdom (4) · Italy (3) · Netherlands (3) · Spain (3) · Czechia (2) · France (2) · Australia (1) · Austria (1) · Hungary (1) · Ireland (1) · Israel (1) · Japan (1)
Gerard O'Sullivan, MD (1) · Gerhard Hamann, Prof. Dr (1) · Hatice Nida Sen, MD, MHSc (1) · Peter Verhamme, MD, PhD (1) · Steven D Schwartz, M.D. (1) · Vincent Thijs, MD PhD (1)
PMID 22879421, PMID 22894573, PMID 23033391, PMID 26068086, PMID 23982845, PMID 30350717, PMID 34250257
2015 (1)